Phil Collis, PhD, is the Senior Vice President, Drug Development at BioCryst Pharmaceuticals, based in Research Triangle Park, North Carolina. Following a PhD at the Middlesex Hospital School of Medicine, University of London and post-doctoral studies at the MRC National Institute of Medical Research, Mill Hill, UK, Phil started his career in clinical and drug development at Glaxo/Glaxo Wellcome in the UK. He has since pursued his passion for drug development in a clinical CRO and, for the last 17 years, at BioCryst Pharmaceuticals, where he led the team responsible for the development and approval of the company’s first product in a rare disease. Phil currently supports the non-clinical and clinical development teams that are focused on the development of novel therapeutics for a range of rare diseases in patients with serious unmet medical needs.
Tuesday, September 12, 2023
3:30 PM - 5:00 PM PT
Disclosure(s): BioCryst Pharmaceuticals: Employment (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) ()
2 - Opportunities for Accelerating the Drug Development Process in Rare Diseases
Tuesday, September 12, 2023
3:30 PM - 5:00 PM PT
Disclosure(s): BioCryst Pharmaceuticals: Employment (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) ()